Bioxytran (BIXT) Free Cash Flow (2010 - 2026)
Bioxytran (BIXT) posted Free Cash Flow of -$238610.0 for Q1 2026, down 0.69% sequentially from -$236971.0 in Q4 2025, and down 42.6% YoY from -$415728.9 in Q1 2025.
Bioxytran (BIXT) Free Cash Flow (2010 - 2026) Analysis & Trends
Bioxytran has reported Free Cash Flow for 17 years, with the latest figure at -$238610.0 in Q1 2026.
- Quarterly Free Cash Flow fell 42.6% year-over-year to -$238610.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$597742.0 (down 36.14% YoY) and the FY2025 annual result came in at -$526455.0, down 38.06% from the prior year.
- Free Cash Flow eased to -$238610.0 in Q1 2026 per BIXT's latest filing, from -$236971.0 in the prior quarter.
- Over five years, Free Cash Flow peaked at -$41474.0 in Q3 2025 and troughed at -$718774.0 in Q3 2022.
- A 5-year average of -$219142.7 and a median of -$154693.0 in 2022 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2024: Free Cash Flow plunged 398.98% in 2022, then surged 78.53% in 2024.
- Over 5 years, Free Cash Flow stood at -$154693.0 in 2022, then surged by 40.12% to -$92626.0 in 2023, then sank by 38.12% to -$127937.0 in 2024, then slumped by 85.22% to -$236971.0 in 2025, then slipped by 0.69% to -$238610.0 in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$238610.0, -$236971.0, and -$41474.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 292.04 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -95.09 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 477.44 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 433.84 Mn |
| 10 | Bioxytran | 2.47 Mn | 2.22 Mn | - | -349,773.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -238,610.00 |
| Mar 31, 2026 | -238,610.00 |
| Dec 31, 2025 | -236,971.00 |
| Dec 31, 2025 | -236,971.00 |
| Sep 30, 2025 | -41,474.00 |
| Sep 30, 2025 | -41,474.00 |
| Jun 30, 2025 | -80,687.00 |
| Jun 30, 2025 | -80,687.00 |
| Mar 31, 2025 | -167,323.00 |
| Mar 31, 2025 | -167,323.00 |
| Dec 31, 2024 | -127,937.00 |
| Dec 31, 2024 | -127,937.00 |
| Sep 30, 2024 | -73,547.00 |
| Sep 30, 2024 | -73,547.00 |
| Jun 30, 2024 | -70,265.00 |
| Jun 30, 2024 | -70,265.00 |
| Mar 31, 2024 | -109,567.00 |
| Mar 31, 2024 | -109,567.00 |
| Dec 31, 2023 | -92,626.00 |
| Dec 31, 2023 | -92,626.00 |